Variability of lipoprotein(a) levels in patients with acute myocardial infarction between admission, discharge, and follow-up
In brief
A discharge lipoprotein(a) test below 37 mg/dL missed high levels in 1%
Among 1,561 people hospitalized with a heart attack, median lipoprotein(a) levels stayed stable, but about one-third shifted between risk categories over time. At discharge, levels at or below 37 mg/dL identified a group in which fewer than 1% later had levels above 70 mg/dL. This two-step testing approach needs external validation before clinical use.
- Journal
- European journal of preventive cardiology (Q1)
- Published
- 8 November 2026
- Study design
- Non-randomized / quasi-experimental trial
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Tabassome Simon, Randa Khani Bittar, Alexandra Rousseau, Fabrice Prunier, Guillaume Cayla, Emile Ferrari, et al.
- PMID
- 42999996
- DOI
- 10.1093/eurjpc/zwag573
Why clinicians should know about it
- Picked for Biochemistry (medical) (top studies of the week, 15 November 2026): Lp(a) measurement variability and repeat-testing strategy
Abstract
AIMS: Lipoprotein(a) [Lp(a)] is an established risk factor for atherosclerotic cardiovascular disease. Using Lp(a) concentrations measured during stable follow-up as the reference, we aimed to assess the temporal variability of Lp(a) after acute myocardial infarction (AMI) and to explore a pragmatic strategy for Lp(a) measurement. METHODS AND RESULTS: The FRENCHIE-Lp(a) cohort enrolled consecutive adults hospitalized for AMI in 21 centres. Lp(a) mass concentration, measured at admission, hospital discharge, and 3-12 months follow-up, was analysed both as a continuous and predefined categorical variable (≤20, >20-≤50, >50-≤70, >70 mg/dL). Assuming follow-up Lp(a) as the reference, we aimed to identify the threshold values that would allow us to accurately identify patients with Lp(a) > 70mg/dL, the threshold mostly used for patient selection in phase III trials of targeted Lp(a) therapies. A cumulative threshold analysis was performed to identify the Lp(a) value below which the misclassification rate (i.e. % of patients with follow-up Lp(a) > 70 mg/dL) remained <1%. Among 1561 patients (aged 61 ± 12 years; 21.3% women), median Lp(a) was 13 mg/dL at admission and remained stable over time (median difference overtime = 0 mg/dL). However, only 68.5% of patients remained in the same Lp(a) category overtime. In patients with discharge-Lp(a) ≤37 mg/dL (72.5% of the population), only 0.97% had Lp(a) >70 mg/dL at follow-up compared to 39.9% of those with discharge-Lp(a) >37 mg/dL. CONCLUSION: Although the median Lp(a) level remained stable between admission and follow-up, one-third of AMI patients shifted within Lp(a) categories over time. Pending external validation, an exploratory two-step strategy based on Lp(a) measurement at discharge, followed by repeat testing in patients with Lp(a) >37 mg/dL, showed a misclassification rate below 1% for identifying patients potentially needing intervention. REGISTRATION: Clinical trial Number: NCT04050956.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.